Nanomedicines & Translational Drug Delivery group

Pleased to share our latest publication of Controlled Release Controlled Release Society exploring the emerging potential of gene therapies delivered by nanomedicine platforms to tackle intestinal fibrosis, a major unmet challenges in inflammatory bowel disease. Intestinal fibrosis, particularly in Crohn’s disease, can lead to irreversible tissue remodelling and stricture formation. While current IBD therapies have transformed the management of inflammation, their ability to prevent or reverse established fibrosis remains limited. Using nanomedicine not simply to deliver conventional drugs, but as a precision platform for delivering genetic therapeutics capable of modulating the molecular pathways driving fibrosis, highlights how RNA-based therapeutics, gene silencing/editing strategies and targeted nanosystems may enable precise intervention in the fibrotic microenvironment.
A fascinating direction for the future of IBD, gene therapy and nanomedicine!

https://www.sciencedirect.com/science/article/pii/S0168365926006462?via%3Dihub

LinkedIn This link will take you to a page that’s not on LinkedIn

This has been an incredibly demanding year for our group, physically and mentally. A year full of challenges, of great news to celebrate, and also a few setbacks along the way. But looking at the bigger picture, it was a positive year, one we can be proud of.
That's why we felt it was essential to step outside the lab and spend a day together in nature to relax, reconnect, and simply enjoy each other's company away from the daily pace of research.
This time outdoors, surrounded by peace and fresh air, was also about preparing ourselves for what's ahead: a new working year that promises to be just as challenging, with even greater responsibilities for all of us.
In the meantime, we're looking forward to squeezing in a few well-deserved vacation days before diving back in.
Grateful for this group, this journey, and everything still to come!

Meet our group member Maria Cazelli!
Maria is a Research Fellow and is currently working on combination nanotherapy for the treatment of Crohn's Disease. You can find more about her work at https://www.i3s.up.pt/personal-info.php?id=6009&idg=109

In her free time, Maria likes to crochet, read books and spend the day by the beach.

'sDisease

Meet our group member Anson Ng!
Anson is a Visiting Researcher from University of Macau, now at Instituto de Investigação e Inovação em Saúde. He is currently working on learning from and observing other students' laboratory work. You can find more about his work at https://www.i3s.up.pt/personal-info.php?id=6024&idg=109
In his free time, Anson likes to engage in photography, writing and learning about history.

It is a great honor to officially begin my term as President of the Controlled Release Society. It was especially meaningful to be inducted in Portugal during .
I look forward to working closely with the CRS community, the Board of Directors (Yoon Yeo, María Vicent, Ryan Donnelly, Vincent Jannin, Laura Ensign, Marianne Ashford, Stephanie Barrett, Juliane Nguyen, Hélder Santos and Luis Brito) and our members to advance the Society's mission, honor our legacy and values, and continue supporting excellence and innovation in delivery science.
I would also like to express my sincere gratitude to our outgoing President, María Vicent, for her outstanding leadership and dedication to the Society.

What a fantastic week at the Controlled Release Society in Lisbon!
It was a privilege to be part of such an inspiring event, bringing together outstanding scientists that have been defining the international field of delivery science as Tanja Weil, Chunying Chen, Paula Hammond, , Michael Bevilacqua, and many others.
We are proud to have shared the exciting work we have been developing at Instituto de Investigação e Inovação em Saúde, in collaboration with many excellent colleagues. Events like provide invaluable opportunities to exchange ideas, foster collaborations and discuss the latest advances that will drive therapeutic delivery technologies.
A heartfelt thanks to the AMPC leaded by Helena Florindo, to Maria Jesus Vicent and to everyone who contributed to making this meeting such a success.

Excited that the 2026 Controlled Release Society Annual Meeting is almost here! It is a privilege to welcome the global delivery science community to for an outstanding scientific meeting. Throughout the congress, our group i3S - Instituto de Investigação e Inovação em Saúde will have a strong presence, contributing with multiple oral presentations, poster presentations and chairing several scientific sessions.
This meeting will be especially meaningful, as will officially begin my term as President. It is a great honour to take on this role while welcoming colleagues from around.
Looking forward to an inspiring week of great science, engaging discussions, new collaborations and an unforgettable CRS Annual Meeting!

https://crs2026annualmeeting.eventscribe.net

CRS 2026 Annual Meeting & Exposition

Honored for the Opening Keynote Speaker at the CRAFT 2026 Research Symposium in and share our latest advances in microengineered 3D multicompartmental models for drug screening across complex tissues and disease models. Fruitful discussions with the CRAFT community on how our next-generation microengineered platforms more faithfully recapitulate the complexity of human physiology, enabling more predictive and translational drug and nanomedicine development.

https://noticias.up.pt/2026/06/17/i3s-lidera-projeto-para-inovar-no-tratamento-do-glioblastoma/

i3S lidera projeto para inovar no tratamento do glioblastoma Projeto para desenvolver nanomedicinas ativadas por ultrassons recebeu financiamento de 150 mil euros do Programa UT Austin Portugal.